Express Pharma

JULY 3, 2023

Many millions of people are vaccinated against COVID-19, thanks to a messenger RNA (mRNA) encapsulated within a lipid nanoparticle. For decades, Waters has been a trusted partner to many pharma and generics companies operating in India, particularly for small molecule QA/QC. How poised are you to leverage them?

Biosimilars 88

Biosimilars Drug Development Generic Medicine Diabetes 88

European Pharmaceutical Review

NOVEMBER 14, 2022

Four medicines recommended for approval in the European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP)’s latest meeting included a biosimilar for osteoporosis and a novel COVID-19 vaccine. COVID-19 update. 5 in children five to 11 years. CHMP’s safety update.

Vaccines 80

Vaccines Biosimilars Generic Medicine 80

European Pharmaceutical Review

FEBRUARY 26, 2024

At its February 2024 meeting, the EMA’s human medicines committee (CHMP) recommended the extension of marketing authorisations for six treatments, and positive opinions for the approval of ten medicines.

Generic Medicine 88

Generic Medicine Vaccines Pharmaceutical Companies Pharmaceutical Companies 88

European Pharmaceutical Review

SEPTEMBER 21, 2022

Biosimilar medicine Ximluci (ranibizumab) for the treatment of neovascular age-related macular degeneration, a progressive retinal macular disease, causing gradual vision impairment, mainly in the elderly population. Adapted vaccines Comirnaty Original/Omicron BA.1 Adapted vaccines Comirnaty Original/Omicron BA.1

Generic Medicine 96

Generic Medicine Vaccines Biosimilars 96

European Pharmaceutical Review

APRIL 3, 2023

It is the eighth vaccine recommended in the European Union (EU) for COVID-19. The CHMP adopted a positive opinion for Epysqli (eculizumab), a biosimilar medicine for paroxysmal nocturnal haemoglobinuria. The committee adopted a positive opinion for Briumvi (ublituximab) for relapsing multiple sclerosis (MS).

Vaccines 82

Vaccines Chemotherapy Generic Medicine Biosimilars 82

Quality Matters

APRIL 20, 2023

Launched in 2021 and composed of more than 250 million data points spanning 92% of generic medicines approved in the U.S., Perhaps most noticeably during the COVID-19 pandemic, this included approval or authorization of an unprecedented number of novel vaccines that help save lives.

Biosimilars 52

Biosimilars Labelling Vaccines Generic Medicine 52